Integrity Bio

Integrity Bio

Integrity Bio
Exhibitor Spotlight

INTERPHEX created a quick questionnaire to learn more about Integrity Bio In this exhibitor spotlight, Michael Reilly, answers our questions.

INTERPHEX: - Tell us how your company started.

We are formulation and manufacturing experts from Amgen and Baxter that started a formulation contract services business over 15 years ago. We added GMP fill finish 10 years ago, and continue to grow our clinical manufacturing services.

INTERPHEX: - How has your company evolved into what it is today?

New customers often remain with us for multiple products in their portfolio which has driven our organic growth. We expect to complete a doubling of our parenteral manufacturing capacity in mid-2019.

INTERPHEX: - How has the industry changed/evolved?

The mix of products continues to change. We started with proteins, focused on antibodies, and now see a wide mix of parenteral products.

INTERPHEX: - Can you describe three aspects that have allowed your company to succeed?

INTERPHEX: - What is your company’s biggest success thus far?

INTERPHEX: - What is your biggest success thus far?

INTERPHEX: - What distinguishes your company from others in the industry?

Our flexibility. We routinely work with very large and very small companies to deliver their clinical product in an efficient manner.

INTERPHEX: - What is the biggest challenge in your industry?

Contract manufacturing of individualized therapies. The evolving needs and high flexibility requirements will test all manufacturers to deliver a cost-effective service.

INTERPHEX: - Where do you see the industry going in the next 10 years?

INTERPHEX: - What would you consider to be a major achievement for the industry in the coming years?

INTERPHEX: - What advice would you give to a professional starting out in the industry that you wish you would have known?

INTERPHEX: - What don't most people realize about you or your company?

In addition to contract services, we offer some unique technologies for virus/viral vector stabilization, high concentration stabilization, and lyo product delivery. These can provide unique benefits that patients and firms value.

INTERPHEX: - What is your favorite INTERPHEX memory?

INTERPHEX: - Can you describe how you have grown your business at INTERPHEX events?

INTERPHEX: - What are you looking forward to at INTERPHEX this year?

This is our first time at Interphex and we are excited to share our subsidiary Vaccine Stabilization Institute’s proprietary formulation technology using blended amino acids. The technology is applied to an enveloped virus and stabilizes the virus in liquid and freeze-dried states. We’re presenting novel data on the INNOPHEX Stage on Wednesday April 3, 2019 at 4:15pm - 5: 00pm.

INTERPHEX: - Is there anything that you would like to specifically see at INTERPHEX 2019?

We use cookies to operate this website and to improve its usability. Full details of what cookies are, why we use them and how you can manage them can be found by reading our Privacy & Cookies page. Please note that by using this site you are consenting to the use of cookies.